Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : momo-T/FIF -- Ignore unavailable to you. Want to Upgrade?

To: tuck who wrote (11145)	6/21/2017 3:19:39 PM
From: tuck	Read Replies (1) \| Respond to of 12215

CARA: So today the IV pain trials powering readout hit, and the news is OK. Enrollment continues and is expected to complete by year end, giving an efficacy and safety readout in 1H18. "No significant changes in the monitored safety parameters." This includes serum sodium levels, the parameter that caused the hold and dose reduction. I gather that, even if the IDMC hadn't seen any efficacy, the trial would not have been stopped for futility (I don't think they were even looking at that). However, the fact that they are not having to add patients and thus delay the readout suggests at least some efficacy is there. So overall, this derisks the IV pain indication (and to a lesser extent, the other indications), and the stock is up ~9%. I continue to hold my put insurance against the shares in my taxable account, waiting for the oral OA results to hit. In my IRA, where I don't do options, my only money management strategy available was to sell a chunk. There I sold half a few minutes ago at $19.45, and expect to hold the remainder for some time. Back of the envelope numbers suggest the pruritus indication alone justifies the share price. Thus, if there were a flop in the pain indications and the stock tanked below mid-teens, I would add, in both accounts. Cheers, Tuck